Ten days after receiving the second dose of messenger RNA vaccine, or mRNA, vaccine for COVID-19, patients without COVID-19 symptoms are significantly more likely to test positive and unknowingly dispense COVID-19, compared to patients who do not received the vaccine for COVID19. The Pfizer-BioNTech and Moderna messenger RNA vaccines for COVID-19 are authorized for emergency use in the US
With two doses of messenger RV COVID-19 vaccine, people without symptoms showed an 80% lower risk of change for a positive test for COVID-19 after their last dose. These are the results of a study from the Mayo Clinic of vaccinated patients. These results will appear in the journal Clinical infectious diseases.
The authors state that these findings confirm the effectiveness of messenger RNA vaccines for COVID-19 to severely limit the transmission of COVID-19 by people with no symptoms that could spread the disease to humans. others unknowingly.
The researchers looked back at a group of 39,000 patients who underwent preclinical molecular screening tests for COVID-19. More than 48,000 screening tests were performed, including 3,000 screening tests on patients who had received at least one dose of COVID-19 RNA vaccine.
These screening tests were part of routine COVID-19 tests prior to non-COVID-19 treatments, such as surgeries and other procedures. Patients in the vaccination group had received at least one dose of messenger RV COVID-19 vaccine.
We found that those asymptomatic patients receiving at least one dose of the first authorized COVID-19 mRNA vaccine, Pfizer-BioNTech, 10 days or more before the screening were 72% less likely to test positive. to do. Those receiving two doses were 73% less likely, compared to the unvaccinated group. “
Aaron Tande, MD, Study C.oFirst A.uthor and Infectious Diseases Specialist, Mayo Clinic
After adjusting for several factors, researchers found an 80% risk reduction of a positive test for COVID-19 among those with two doses of COVID-19 messenger RNA vaccine. The study was based on patients who underwent screening tests between Dec. 17, 2020, and Feb. 8 at the Mayo Clinic in Minnesota and Arizona and at the Mayo Clinic Health System in Minnesota and Wisconsin.
Source:
Magazine Reference:
Tande, AJ, et al. (2021) Effect of COVID-19 vaccine on Asymptomatic Disease among patients receiving preoperative COVID-19 molecular screening. Clinical infectious diseases. doi.org/10.1093/cid/ciab229.